AVITA Q3 2025 Press Release

• Commercial revenue of $17.1 million, a 13% decrease
• Cash, cash equivalents, and marketable securities of $23.3 million
• Operating expenses decreased by 24% to $23.0 million

AVITA Medical reported financial results for the third quarter of 2025, with commercial revenue of $17.1 million, representing a 13% decrease compared to the same period in 2024. The company's cash, cash equivalents, and marketable securities totaled $23.3 million as of September 30, 2025. Operating expenses decreased by 24%, or $7.2 million, to $23.0 million, as the company continues to streamline operations and align spending with growth priorities. Net loss improved to $13.2 million, or $0.46 per basic and diluted share, from $16.2 million, or $0.62 per share, in Q3 2024. AVITA Medical received CE Mark approval for RECELL GO under the EU Medical Device Regulation, enabling European launch beginning with Germany, Italy, and the United Kingdom. Clinical data and conference presentations continue to reinforce the company's leadership in acute wound care. AVITA Medical now expects full-year 2025 revenue of $70 to $74 million, compared with prior guidance of $76 to $81 million.

AVITA Medical now expects full-year 2025 revenue of $70 to $74 million, compared with prior guidance of $76 to $81 million.

AVITA Medical is exploring opportunities to enhance financial flexibility and support continued execution of revenue growth. The company expects to provide an update on its capital and growth plans, along with 2026 guidance, in the first quarter of 2026.